{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:09:37Z","timestamp":1782756577751,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Patients with hematologic malignancy had the possibility of persistent infection with COVID-19, particularly those who received anti-CD20 monoclonal antibody therapy for lymphoma, regardless of vaccination status. We report two cases of follicular lymphoma (FL) infected with Omicron virus that could not be confirmed by routine SARS-CoV-2 tests during maintenance therapy with an anti-CD20 agent, obinutuzumab or rituximab. In addition to immunomodulatory drugs, both of them took Simnotrelvir\/Ritonavir to effectively alleviate the symptoms. The aim is to highlight the complexity of SARS-CoV-2 infection and to discuss why it is easy to be infected with COVID-19 for a long time in this fragile patient population and the response to such patients with unexplained respiratory symptoms during maintenance therapy. Patients with hematologic malignancies treated with anti-CD20 agent are at considerable risk of a prolonged disease course and recurrence of COVID-19. Specialized prevention, diagnostic and therapeutic strategies should be developed for this group of patients.<\/jats:p>","DOI":"10.3389\/fonc.2025.1583932","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:35:44Z","timestamp":1755063344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Simnotrelvir\/Ritonavir are effective in shortening the course of prolonged SARS-CoV-2 infection during anti-CD20 maintenance therapy in patients with follicular lymphoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Jing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengke","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000523872","article-title":"COVID-19 in patients with hematologic Malignancies: clinical manifestations, persistence, and immune response","volume":"145","author":"Gur","year":"2022","journal-title":"Acta Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000841","article-title":"Long and persistent COVID-19 in patients with hematologic Malignancies: from bench to bedside","volume":"35","author":"Laracy","year":"2022","journal-title":"Curr Opin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00215-2","article-title":"Where did Omicron come from? Three key theories","volume":"602","author":"Mallapaty","year":"2022","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California","volume":"28","author":"Lewnard","year":"2022","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2022.092","article-title":"Casirivimab\/imdevimab for active COVID-19 pneumonia which persisted for nine months in a patient with follicular lymphoma during anti-CD20 therapy","volume":"75","author":"Nagai","year":"2022","journal-title":"Jpn J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020220","article-title":"Oral nirmatrelvir\/ritonavir therapy for COVID-19: the dawn in the dark","volume":"11","author":"Hung","year":"2022","journal-title":"Antibiot (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/v14112540","article-title":"Oral antiviral treatment for COVID-19: A comprehensive review on nirmatrelvir\/ritonavir","volume":"14","author":"Akinosoglou","year":"2022","journal-title":"Viruses"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000801","article-title":"Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-coV-2 3C-like protease, across animals and humans","volume":"50","author":"Eng","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.3c00134","article-title":"Deuremidevir and simnotrelvir-ritonavir for the treatment of COVID-19","volume":"6","author":"Zhu","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1207225","article-title":"Omicron related COVID-19 prevention and treatment measures for patients with hematological Malignancy and strategies for modifying hematologic treatment regimes","volume":"13","author":"Guo","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10238-024-01381-5","article-title":"Managing and treating COVID-19 in patients with hematological Malignancies: a narrative review and expert insights","volume":"24","author":"Ng","year":"2024","journal-title":"Clin Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18782","article-title":"Systematic review and meta-analysis of the clinical effectiveness of tixagevimab\/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients","volume":"201","author":"Suribhatla","year":"2023","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0112","article-title":"Obinutuzumab in the treatment of B-cell Malignancies: a comprehensive review","volume":"18","author":"Davies","year":"2022","journal-title":"Future Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic Malignancies: A review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41563-020-00906-z","article-title":"Diagnostics for SARS-coV-2 infections","volume":"20","author":"Kevadiya","year":"2021","journal-title":"Nat Mater"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e7861","DOI":"10.1002\/ccr3.7861","article-title":"Prolonged SARS-CoV-2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report","volume":"11","author":"Kambe","year":"2023","journal-title":"Clin Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/v15030693","article-title":"Prolonged SARS-coV-2 infection and organizing pneumonia in a patient with follicular lymphoma, treated with obinutuzumab-challenging recognition and treatment","volume":"15","author":"\u0141y\u017cwa","year":"2023","journal-title":"Viruses"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0536","article-title":"Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin\u2019s lymphoma","volume":"17","author":"Cerhan","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07528.x","article-title":"BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations","volume":"144","author":"Masir","year":"2009","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.8190","article-title":"t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma","volume":"32","author":"Roulland","year":"2014","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2024-0405","article-title":"Biological and clinical relevance of genetic alterations in peripheral T-cell lymphomas","volume":"8","author":"Ito","year":"2025","journal-title":"Jma J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.72663","article-title":"Signaling mechanisms of SARS-CoV-2 Nucleocapsid protein in viral infection, cell death and inflammation","volume":"18","author":"Wang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016650117","article-title":"SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling","volume":"117","author":"Miorin","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940756","article-title":"Roles and functions of SARS-CoV-2 proteins in host immune evasion","volume":"13","author":"Rashid","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.860891","article-title":"Persistence of SARS-coV-2 infection in severely immunocompromised patients with complete remission B-cell lymphoma and anti-CD20 monoclonal antibody therapy: A case report of two cases","volume":"13","author":"Mart\u00ednez-Chinchilla","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2887","article-title":"Rebound of COVID-19 with nirmatrelvir-ritonavir antiviral therapy","volume":"176","author":"Cohen","year":"2023","journal-title":"Ann Intern Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e241765","DOI":"10.1001\/jamanetworkopen.2024.1765","article-title":"COVID-19 rebound after VV116 vs nirmatrelvir-ritonavir treatment: A randomized clinical trial","volume":"7","author":"Yang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac663","article-title":"Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir\/ritonavir treatment","volume":"76","author":"Epling","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0162324","DOI":"10.1128\/jvi.01623-24","article-title":"Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance","volume":"99","author":"Phan","year":"2025","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:35:45Z","timestamp":1755063345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":35,"alternative-id":["10.3389\/fonc.2025.1583932"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1583932","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1583932"}}